AR055100A1 - Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato - Google Patents

Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato

Info

Publication number
AR055100A1
AR055100A1 ARP060103273A ARP060103273A AR055100A1 AR 055100 A1 AR055100 A1 AR 055100A1 AR P060103273 A ARP060103273 A AR P060103273A AR P060103273 A ARP060103273 A AR P060103273A AR 055100 A1 AR055100 A1 AR 055100A1
Authority
AR
Argentina
Prior art keywords
alkylene
group
nr6r7
alkyl
independently selected
Prior art date
Application number
ARP060103273A
Other languages
English (en)
Inventor
Methvin Isaac
Malik Slassi
Ian Egle
Fupeng Ma
Original Assignee
Astrazeneca Ab
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Nps Pharma Inc filed Critical Astrazeneca Ab
Publication of AR055100A1 publication Critical patent/AR055100A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1): en donde A se selecciona del grupo formado por CR8R9, NR5, O, S, SO y SO2, B se selecciona del grupo formado por CH y N; D se selecciona del grupo formado por NH, N-C1-6-alquilo, y -(CR5R6)z-, en donde uno de los grupos -CR5R6- se puede reemplazar por -C(O)-, NH, o NC1-6-alquilo; L se selecciona del grupo formado por un enlace directo y -(CR5R6)w-, en donde cuando L es -(CR5R6)w; (i) B-L pueden ser insaturados, o dos átomos de carbono adyacentes pueden formar parte de un anillo ciclopropilo; o (ji) uno o dos grupos CR5R6 se puede reemplazar con O, S, o NR5; el resto de formula (2) representa un anillo seleccionado entre el grupo formado por azetidina y un anillo de 5 a 7 miembros, que pueden ser insaturados, en donde el anillo puede estar sustituido por uno o más R4; R1en cada caso, se selecciona del grupo formado por H, F, Cl, Br, I, OH, CN, nitro, C1-6-alquilo, OC1-6-alquilo, C1-6-alquilhalo, OC1-6-alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, C3-8-cicloalquilo, C1-6-alquilen-C3-8-cicloalquilo, OC0-6- alquilen-C3-8-cicloalquilo, arilo, heteroarilo, C1-6-alquilenoarilo, C1-6-alquilenoheteroarilo, OC1-6- alquilenoarilo, OC1-6- alquilenoheteroarilo, C1-6-alquilenoheterocicloalquilo, (CO) R5, (CO)OR5, C1-6-alquilenoOR5, OC2-6-alquilenoOR5, C1-6-alquileno (CO)R5, OC1-6-alquileno(CO)R5, C1-6-alquilenociano, OC2-6-alquilenociano, C0-6-alquilenoNR6R7, OC2-6-alquilenoNR6R7, C1-6- alquileno(CO)NR6R7, OC1-6-alquileno(CO) NR6R7, C0-6-alquilenoNR6(CO)R7, OC2-6-alquilenoNR6(CO)R7, C0-6-alquilenoNR6(CO)NR6R7, C0-6-alquilenoSO2R5, OC2-6-alquilenoSO2R5, C0--6-alquileno (SO2) NR6R7, OC2-6-alquileno (SO2)NR6R7, C0-6-alquilenoNR6 (SO2)R7, OC2-6-alquilenoNR6 (SO2)R7', C0-6- alquilenoNR6(SO2)NR6R7, OC2-6-alquilenoNR6(SO2)NR6R7, (CO)NR6R7 y SO3R5, en donde cualquier grupo cíclico puede estar también sustituido con uno o más grupos R2; R2 y R4, en cada caso, se seleccionan en forma independiente entre el grupo formado por H, F, Cl, Br, I, CN, nitro, hidroxi, oxo, C1-6-alquilo, OC1-6-alquilo, C1-6-alquilhalo, OC1-6-alquilhalo y C0-6-alquilenoNR5R6; R3 es un sistema de anillo de 5 a 12 miembros que es opcionalmente sustituido por hasta tres grupos R1, en donde el sistema de anillo puede contener uno o más heteroátomos seleccionados en forma independiente entre el grupo formado por N, O y S; R5 se selecciona del grupo formado por H, C1-6-alquilo, arilo, C3-8- cicloalquilo, C1-6-alquilenoarilo y C1-6-alquilen-C3-8-cicloalquilo, en donde cualquier grupo cíclico puede estar también sustituido con uno o más grupos R2 seleccionados en forma independiente; R6 y R7 se seleccionan en forma independiente entre el grupo formado por H, y C1-6- alquilo; R8 y R9 se seleccionan en forma independiente entre el grupo formado por H, -O-(CH2)2-O- y -O-(CH2)3-O-; m y n son enteros seleccionados en forma independiente entre el grupo formado por 0, 1, 2, 3 y 4, con la salvedad de que m y n no pueden ser simultáneamente 0; x y y son enteros seleccionados en forma independiente entre el grupo formado por 1, 2, y 3; y w y z'. son enteros seleccionados en forma independiente entre el grupo formado por 1, 2, 3, 4, 5, y 6; o una sal aceptable para uso farmacéutico, hidrato, solvato, isoforma, tautomero, isomero optico, o combinacion de los mismos.
ARP060103273A 2005-08-05 2006-07-28 Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato AR055100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70547105P 2005-08-05 2005-08-05

Publications (1)

Publication Number Publication Date
AR055100A1 true AR055100A1 (es) 2007-08-08

Family

ID=37607094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103273A AR055100A1 (es) 2005-08-05 2006-07-28 Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato

Country Status (17)

Country Link
US (2) US20070032469A1 (es)
EP (1) EP1912989A2 (es)
JP (1) JP2009503069A (es)
KR (1) KR20080035576A (es)
CN (1) CN101268077A (es)
AR (1) AR055100A1 (es)
AU (1) AU2006279034A1 (es)
BR (1) BRPI0614168A2 (es)
CA (1) CA2616020A1 (es)
EC (1) ECSP088128A (es)
IL (1) IL188809A0 (es)
MX (1) MX2008001152A (es)
NO (1) NO20080475L (es)
RU (1) RU2008101923A (es)
TW (1) TW200745112A (es)
UY (1) UY29710A1 (es)
WO (1) WO2007018998A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007065655A1 (en) * 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP2010525073A (ja) * 2007-04-23 2010-07-22 ハウス イアー インスティトゥート 代謝型グルタミン酸受容体７の調節による老人性難聴の治療及び／又は予防
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
EA017648B1 (ru) * 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
CA2704436C (en) * 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
JP2011520890A (ja) * 2008-05-15 2011-07-21 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
EP2279532A4 (en) * 2008-05-15 2011-07-27 Merck Sharp & Dohme OXAZOLBENZIMIDAZOLDERIVATE
KR101653707B1 (ko) * 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도
US20110171134A1 (en) * 2008-06-25 2011-07-14 Iskandar Bermans J (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
US20110178117A1 (en) * 2008-09-26 2011-07-21 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
GB201220157D0 (en) * 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
CN102964292A (zh) * 2012-11-26 2013-03-13 盛世泰科生物医药技术(苏州)有限公司 4-（2-（三氟甲氧基）苯基）哌啶的合成
EA035469B1 (ru) * 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR101672096B1 (ko) * 2013-09-30 2016-11-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015154047A1 (en) * 2014-04-03 2015-10-08 Restorgenex Corporation Novel methods
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
JP6579549B2 (ja) 2014-05-16 2019-09-25 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
JP6599979B2 (ja) * 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
AU2016271762B2 (en) * 2015-05-29 2020-01-23 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
US10065970B2 (en) 2015-09-08 2018-09-04 Genentech, Inc. Tricyclic PI3K inhibitor compounds and methods of use
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
CN112351778B (zh) * 2018-06-28 2023-04-04 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
CN113631535B (zh) * 2019-03-11 2024-04-12 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN116283758B (zh) * 2023-03-30 2024-05-24 安徽工业大学 一种喹啉合成n-甲酰基四氢喹啉的方法及产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
HRP20030081A2 (en) * 2000-08-08 2005-02-28 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
US6887996B2 (en) * 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use

Also Published As

Publication number Publication date
EP1912989A2 (en) 2008-04-23
TW200745112A (en) 2007-12-16
ECSP088128A (es) 2008-02-20
CN101268077A (zh) 2008-09-17
US20080318999A1 (en) 2008-12-25
JP2009503069A (ja) 2009-01-29
AU2006279034A1 (en) 2007-02-15
UY29710A1 (es) 2007-02-28
RU2008101923A (ru) 2009-09-10
KR20080035576A (ko) 2008-04-23
MX2008001152A (es) 2008-04-02
WO2007018998A3 (en) 2007-05-03
IL188809A0 (en) 2008-08-07
NO20080475L (no) 2008-04-15
US20070032469A1 (en) 2007-02-08
CA2616020A1 (en) 2007-02-15
BRPI0614168A2 (pt) 2017-07-25
WO2007018998A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
PE20040909A1 (es) Derivados fluoroglicosidos aromaticos con afinidad por el receptor sglt2
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
CO5640084A2 (es) Ligandos de receptores cannabinoides y sus usos
AR058699A1 (es) Derivados de sulfonamidoanilina como inhibidores de tirosina-quinasas jak-2 y jak-3
CO6241123A2 (es) Moduladores de la gamma secretasa
AR048669A1 (es) Derivados biciclicos de bisamida
UY37310A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CO6321153A2 (es) Derivados de cromeno y cromano y sus usos
ECSP099638A (es) Nuevo compuesto de adenina
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
CO5690548A2 (es) N-arilheterociclos sustituidos, procedimientos para su preparacion y su empleo como medicamentos
AR079510A1 (es) Derivados de quinolinamida moduladores alostericos positivos de receptores muscarinicos m1, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del alzheimer, esquizofrenia y otras patologias del sistema nervioso central.
UY30334A1 (es) Derivados de triazolopirazina
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
MY139571A (en) Indolyl derivatives as liver-x-receptor modulators
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
AR065280A1 (es) Agentes antiparasitarios
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
AR064517A1 (es) Pirimidinionas biciclicas y sus usos
AR057728A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotropicos. composiciones farmaceuticas.
AR049398A1 (es) Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados.
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
CO6170405A2 (es) Composicion plaguicida que comprende fluopicolida y un compuesto insecticida
AR070187A1 (es) Derivados de dulfonamidas sustituidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure